X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24449) 24449
Magazine Article (161) 161
Book Chapter (64) 64
Conference Proceeding (17) 17
Book / eBook (16) 16
Book Review (14) 14
Newsletter (14) 14
Dissertation (6) 6
Publication (6) 6
Reference (4) 4
Web Resource (4) 4
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21137) 21137
angiotensin-converting enzyme inhibitors - therapeutic use (18592) 18592
male (10902) 10902
female (9390) 9390
middle aged (7375) 7375
hypertension - drug therapy (6963) 6963
aged (6459) 6459
antihypertensive agents - therapeutic use (4694) 4694
animals (4553) 4553
hypertension (4431) 4431
cardiac & cardiovascular systems (4300) 4300
adult (4299) 4299
adrenergic beta-antagonists - therapeutic use (3841) 3841
heart failure - drug therapy (3793) 3793
treatment outcome (3398) 3398
blood pressure - drug effects (3370) 3370
angiotensin-converting enzyme inhibitors - pharmacology (3145) 3145
pharmacology & pharmacy (3065) 3065
risk factors (2974) 2974
drug therapy, combination (2961) 2961
mortality (2672) 2672
angiotensin (2545) 2545
calcium channel blockers - therapeutic use (2540) 2540
angiotensin-converting enzyme inhibitors - adverse effects (2434) 2434
medicine, general & internal (2400) 2400
heart failure (2372) 2372
peripheral vascular disease (2330) 2330
angiotensin-converting enzyme inhibitors (2317) 2317
diuretics - therapeutic use (2257) 2257
renin-angiotensin system - drug effects (2249) 2249
ace inhibitors (2178) 2178
hypertension - physiopathology (2170) 2170
rats (2133) 2133
angiotensin ii type 1 receptor blockers - therapeutic use (1982) 1982
blood-pressure (1955) 1955
angiotensin-converting enzyme (1857) 1857
hypertension - complications (1801) 1801
enalapril - therapeutic use (1771) 1771
angiotensin-converting enzyme inhibitors - administration & dosage (1769) 1769
captopril (1701) 1701
aged, 80 and over (1686) 1686
time factors (1683) 1683
enzymes (1663) 1663
blood pressure (1649) 1649
urology & nephrology (1611) 1611
double-blind method (1578) 1578
drug therapy (1577) 1577
captopril - therapeutic use (1524) 1524
enalapril (1515) 1515
follow-up studies (1462) 1462
heart failure - physiopathology (1445) 1445
angiotensin receptor antagonists - therapeutic use (1430) 1430
clinical trials as topic (1405) 1405
angiotensin receptor antagonists (1398) 1398
randomized controlled trials as topic (1397) 1397
retrospective studies (1335) 1335
prognosis (1272) 1272
prospective studies (1269) 1269
renin-angiotensin system (1258) 1258
care and treatment (1252) 1252
therapy (1249) 1249
myocardial infarction - drug therapy (1247) 1247
myocardial-infarction (1237) 1237
risk (1165) 1165
medicine & public health (1134) 1134
disease (1081) 1081
diabetes (1049) 1049
disease progression (1036) 1036
heart-failure (1010) 1010
prevention (994) 994
research (985) 985
health aspects (983) 983
renin-angiotensin system - physiology (976) 976
chronic disease (964) 964
analysis (945) 945
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (939) 939
dose-response relationship, drug (904) 904
survival (890) 890
management (887) 887
cardiology (882) 882
hemodynamics - drug effects (879) 879
left-ventricular dysfunction (876) 876
antihypertensive agents - pharmacology (870) 870
adolescent (867) 867
diuretics (857) 857
proteinuria (847) 847
angiotensin converting enzyme (840) 840
cardiovascular disease (828) 828
ramipril - therapeutic use (825) 825
abridged index medicus (816) 816
heart failure - mortality (814) 814
enzyme inhibitors (800) 800
cardiovascular diseases - prevention & control (781) 781
converting enzyme-inhibitors (772) 772
double-blind (761) 761
acute myocardial-infarction (759) 759
antihypertensive agents - adverse effects (755) 755
internal medicine (753) 753
morbidity (752) 752
trial (750) 750
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21720) 21720
German (761) 761
Japanese (528) 528
French (498) 498
Russian (474) 474
Spanish (225) 225
Italian (213) 213
Chinese (117) 117
Polish (112) 112
Portuguese (65) 65
Hungarian (61) 61
Dutch (52) 52
Danish (48) 48
Czech (47) 47
Swedish (32) 32
Norwegian (27) 27
Finnish (24) 24
Romanian (19) 19
Hebrew (16) 16
Ukrainian (15) 15
Serbian (12) 12
Croatian (11) 11
Lithuanian (11) 11
Turkish (11) 11
Slovak (9) 9
Bosnian (1) 1
Bulgarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
... blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 8, p. CD009096
Background Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Angiotensin Receptor Antagonists | Angiostensin‐converting enzyme (ACE) inhibitors | Pharmacological Therapies | Hypotension | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | Heart Diseases | Antihypertensive Agents | Heart & circulation | Essential Hypertension | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | LONG-TERM | Antihypertensive Agents [adverse effects; therapeutic use] | LOSARTAN | Randomized Controlled Trials as Topic Stroke [mortality] | MYOCARDIAL-INFARCTION | Angiotensin-Converting Enzyme Inhibitors [adverse effects; therapeutic use] | HEART-FAILURE | RANDOMIZED CONTROLLED-TRIAL | COMBINATION | Heart Diseases [mortality] | MEDICINE, GENERAL & INTERNAL | HIGH-RISK PATIENTS | Hypertension [complications; drug therapy; mortality] | RAMIPRIL | P-WAVE DISPERSION | LEFT-VENTRICULAR MASS | Angiotensin Receptor Antagonists [adverse effects; therapeutic use] | Humans | Hypertension - drug therapy | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Heart Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Hypertension - complications | Hypertension - mortality | Stroke - mortality | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 12, pp. 1091 - 1099
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, p. CD001841
...: What class of drug to use first‐line? This review attempted to answer that question. Objectives To quantify the mortality and morbidity effects from different first... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Sodium Chloride Symporter Inhibitors | Pharmacological Therapies | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | General Pharmacotherapies | Calcium Channel Blockers | Coronary Disease | Adrenergic beta‐Antagonists | Antihypertensive Agents | Heart & circulation | Thiazides | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Angiotensin-Converting Enzyme Inhibitors [therapeutic use] | Antihypertensive Agents [adverse effects; therapeutic use] | Coronary Disease [prevention & control] | Humans | ELDERLY PROGRAM SHEP | CONVERTING-ENZYME-INHIBITION | Sodium Chloride Symporter Inhibitors [therapeutic use] | Adrenergic beta-Antagonists [therapeutic use] | EUROPEAN-WORKING-PARTY | PROSPECTIVELY-DESIGNED OVERVIEWS | Calcium Channel Blockers [therapeutic use] | SERUM URIC-ACID | MEDICINE, GENERAL & INTERNAL | AUSTRALIAN THERAPEUTIC TRIAL | HIGH-BLOOD-PRESSURE | ISOLATED SYSTOLIC HYPERTENSION | PLACEBO-CONTROLLED TRIAL | Stroke [prevention & control] | CORONARY-HEART-DISEASE | Hypertension [drug therapy; mortality] | Stroke - prevention & control | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Sodium Chloride Symporter Inhibitors - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Thiazides - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypertension - mortality | Adrenergic beta-Antagonists - therapeutic use | Thiazides - therapeutic use
Journal Article